HCW Biologics Posts $2.83 Per-Share Q3 Loss as Cash Crunch Deepens
HCWB is trading near its 52-week low of $0.764 (2.0% above the low) on light trading volume (0.1× avg).
Summary
HCW Biologics reported a third-quarter net loss of $3.2 million, or $2.83 per share, a steep per-share figure that reflects the company's tiny share count after the June 30 reverse split. The loss lands on top of a Q2 that already showed $5.2 million of red ink and a going-concern warning with just $741,324 of cash on hand. The company has been plugging the hole with small raises: a $1.5 million private placement in September and a $10.0 million secured debt facility with Streeterville Capital that closed November 4, only $3.0 million of which came in cash upfront. With the stock at $0.78 and near its 52-week low, the equity is pricing in continued dilution risk from the remaining $7.0 million debt tranche and the resale registrations tied to Armistice Capital.
At the time of this announcement, HCWB was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.76 to $23.94. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.